Kite Reports P-III Study (ZUMA-7) Results of Yescarta for Initial Treatment of Relapsed/Refractory Large B-cell Lymphoma
Shots:
- The P-III study (ZUMA-7) evaluated Yescarta vs SoC in a ratio (1:1) in 359 patients with r/r LBCL within 12mos. at 77 centers globally
- The results showed an improvement in OS over historical treatment, a 2.5-fold increase in patients (40.5% vs 16.3%) who were alive @2yrs. and did not experience cancer progression or need additional cancer treatment and a 4-fold greater m-EFS (8.3 vs 2.0mos.)
- Patients responded to Yescarta, ORR (83% vs 50%) & CR rate (65% vs 32%), ≥50% in the SOC arm received Yescarta off study at the time of the primary EFS analysis. The safety profile was consistent with prior studies, grade ≥3 CRS & neurologic events were seen in 7% & 25% while 83% had high-grade events in the SOC arm
Ref: Businesswire | Image: Kite
Related News:- Kite’s Yescarta Receives EC’s Approval as 2L Treatment of Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
